Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates

Aug 03, 2015, 16:15 ET from Discovery Laboratories, Inc.

WARRINGTON, Pa., Aug. 3, 2015 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a live teleconference and webcast at 8:30 a.m. Eastern Time on Tuesday August 11, 2015 at which time management will discuss the 2015 second quarter financial results along with providing other business updates. The company will issue a press release announcing the second quarter 2015 financial results after the close of the U.S. financial markets on Monday, August 10, 2015.

The press release and the live webcast of the conference call will be available via Discovery Labs' corporate website at  The webcast will be made available on the events page.  An archive will be available after the call at the same address.

To participate in the live conference call, please dial (888) 346-0767 (domestic) or (412) 902-4251 (international).  After placing the call, please ask to be joined into the Discovery Labs conference call.  The conference call replay number is (877) 344-7529 (domestic) or (412) 317-0088 (international); please use 10070663 as the replay passcode.

About Discovery Labs Discovery Laboratories, Inc. is a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases.  Pulmonary surfactants are produced naturally in the lung and are essential for normal respiratory function and survival.  If surfactant deficiency or degradation occurs, the air sacs in the lungs can collapse, resulting in severe respiratory diseases and disorders.  Discovery Labs' technology platform includes a novel synthetic peptide-containing (KL4) surfactant that is structurally similar to naturally occurring pulmonary surfactant and proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant.  Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of aerosolized surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.

For more information, please visit the company's website at

SOURCE Discovery Laboratories, Inc.